公开(公告)号：US20140030264A1

公开(公告)日：2014-01-30

申请号：US13863131

申请日：2013-04-15

Applicant: Baylor Research Institute

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  Eynav Klechevsky ,  SangKon Oh

IPC: C07K16/28 ,  C07K14/005 ,  C07K14/47

CPC classification number: C07K16/2896 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/55561 ,  A61K2039/6056 ,  C07K14/005 ,  C07K14/4748 ,  C07K16/2851 ,  C07K2319/00 ,  C07K2319/33 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2760/16134

Abstract: The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.

Abstract translation: 本发明包括分离的抗兰格林疫苗，分离的抗 - 兰格林抗体的羧基末端制备和使用分离的抗 - 兰格林抗体或其结合片段和一种或多种抗原肽的方法，其中当两种或多种抗原 存在肽，肽被包含至少一个糖基化位点的一个或多个接头肽隔开。 本发明还包括用于表达抗Langerin抗原递送载体的分离载体及其制备和用途。